List of Excipients in Branded Drug COREGCR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Physicians Total Care Inc	COREGCR	carvedilol phosphate	54868-6019	CELLULOSE, MICROCRYSTALLINE
Physicians Total Care Inc	COREGCR	carvedilol phosphate	54868-6019	CROSPOVIDONE
Physicians Total Care Inc	COREGCR	carvedilol phosphate	54868-6019	HYDROGENATED CASTOR OIL
Physicians Total Care Inc	COREGCR	carvedilol phosphate	54868-6019	MAGNESIUM STEARATE
Physicians Total Care Inc	COREGCR	carvedilol phosphate	54868-6019	POVIDONE

COREG CR Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

COREG CR is the once-daily extended-release formulation of carvedilol phosphate. Its commercial differentiation depends on multiparticulate controlled-release technology, dose flexibility, and conversion from twice-daily immediate-release carvedilol. The most attractive excipient opportunities are in polymer-coated pellet systems, capsule-fill manufacturing, bioequivalence optimization, stability improvement, and lower-cost generic production.

What is COREG CR and how is it formulated?

COREG CR contains carvedilol phosphate, a nonselective beta-adrenergic and alpha-1 adrenergic blocker used for heart failure, left ventricular dysfunction following myocardial infarction, and hypertension. The product is supplied as extended-release capsules in 10 mg, 20 mg, 40 mg, and 80 mg strengths.[1]

The product uses a multiparticulate delivery design rather than a conventional single-unit tablet. Each capsule contains controlled-release drug-containing particles or beads. This architecture allows the carvedilol dose to be distributed across multiple units, reducing the impact of local manufacturing defects and supporting gradual drug release through the gastrointestinal tract.

The US prescribing information identifies the following inactive ingredients or excipient classes:

Excipient or material	Likely technical function
Sugar spheres	Inert starter cores for drug-layered pellets
Hypromellose	Binder and drug-layering polymer
Povidone	Binder and granulation aid
Ethylcellulose	Water-insoluble release-controlling polymer
Triethyl citrate	Plasticizer for polymer films
Talc	Anti-tacking and coating-process aid
Gelatin	Hard capsule shell
Titanium dioxide	Opacifier and color modifier
FD&C colors	Capsule identification
Pharmaceutical-grade water and processing solvents	Manufacturing media, removed during production

The exact quantitative formula, coating weight gain, pellet size distribution, and process parameters are not fully disclosed in the prescribing information. Those parameters are likely to be central to the product's in vitro release profile and bioequivalence performance.

What excipient strategy protects the COREG CR release profile?

The central excipient strategy is an ethylcellulose-based diffusion barrier applied to drug-layered pellets. Ethylcellulose is water-insoluble but permeable to aqueous media. It controls carvedilol release by limiting water ingress and drug diffusion rather than by rapidly dissolving.

Hypromellose and povidone support formation of the drug layer on sugar spheres. Hypromellose can also contribute to hydration and porosity control. Triethyl citrate lowers the glass-transition temperature of ethylcellulose and improves film formation during aqueous or solvent-based coating. Talc reduces particle adhesion during coating and drying.

The release profile is controlled by several interacting variables:

1. Polymer type and viscosity grade.
2. Ethylcellulose coating weight gain.
3. Plasticizer concentration.
4. Talc loading and dispersion quality.
5. Pellet diameter and surface area.
6. Drug-layer thickness.
7. Capsule fill weight.
8. Residual solvent and moisture.
9. Dissolution-medium pH and surfactant concentration.
10. Manufacturing scale and coating equipment.

A generic manufacturer cannot reliably reproduce the product by matching the ingredient list alone. The critical performance attributes are the coating microstructure, pellet population distribution, drug loading, and dissolution curve across the product's intended pH range.

What formulations are protected by the COREG CR technology?

The relevant protected formulation concept is an extended-release carvedilol composition using coated multiparticulates or beads. The commercial value lies in the combination of:

• Carvedilol or carvedilol phosphate drug layering.
• Inert seed cores.
• Polymer-controlled release coatings.
• Capsule delivery.
• Multiple release populations or coating levels.
• Once-daily pharmacokinetic performance.

Patent families associated with controlled-release carvedilol formulations have included claims directed to compositions, dosage forms, release characteristics, and manufacturing methods. Public patent records identify controlled-release carvedilol work associated with SmithKline Beecham and GlaxoSmithKline, including US Patent No. 7,235,652.[2]

The practical scope of such patents depends on the issued claims, terminal disclaimers, patent-term adjustment, pediatric extension, and any reissue or continuation activity. A formulation that uses a different polymer, different pellet architecture, or a different release mechanism may avoid some composition claims while still facing bioequivalence and regulatory challenges.

Excipient-related claim risk

Excipient choices create several potential infringement pathways:

Design element	Potential patent relevance
Ethylcellulose film coating	May fall within polymer-coating composition claims
Triethyl citrate plasticization	May be recited as a preferred plasticizer
Sugar-sphere drug layering	May support claims directed to pellet construction
Multiple pellet populations	May be relevant to release-profile claims
Capsule-filled beads	May be covered by dosage-form claims
Specific dissolution limits	May be included in functional or performance claims
Manufacturing sequence	May be covered by process claims

A formulation strategy based on the same excipient classes may still be defensible if the claim requires different ratios, coating architecture, dissolution limits, or manufacturing steps. A freedom-to-operate analysis must compare the proposed formulation with the issued claims, not merely with the product label.

When does COREG CR lose exclusivity?

COREG CR’s commercial exclusivity has several separate components:

Exclusivity category	Relevance
New drug application exclusivity	Related to the original FDA approval
Formulation patent protection	Directed to controlled-release carvedilol technology
Method-of-use patents	May cover specific patient populations or indications
Pediatric exclusivity	Can add six months to qualifying listed patent or exclusivity periods
Regulatory exclusivity for an authorized generic	Contractual or commercial rather than statutory

Carvedilol itself is an established active ingredient. The principal barrier to competition has therefore been the extended-release formulation rather than compound exclusivity.

The FDA Orange Book is the controlling public source for currently listed patents and regulatory exclusivity associated with the reference product.[3] Patent expiration dates should be assessed by patent number, including patent-term adjustment and any pediatric extension. A headline expiration date for one patent does not establish the end of all protection.

What is the Orange Book status of COREG CR?

COREG CR is listed by FDA as an extended-release carvedilol product under an approved new drug application. The Orange Book identifies patents and exclusivity information for approved drug products when the sponsor has submitted qualifying information.[3]

A commercial review should distinguish among:

• The reference product listed under the brand name COREG CR.
• Carvedilol immediate-release tablets.
• Generic carvedilol phosphate extended-release capsules.
• Authorized or licensed alternatives.
• Products discontinued for commercial reasons but still relevant as reference products.

The Orange Book does not disclose the full quantitative excipient formula, pellet coating process, or manufacturing batch parameters. Those details must be reconstructed from product labeling, public regulatory documents, patent disclosures, analytical testing, and reverse-engineering work.

Which companies are challenging COREG CR?

Competition has focused on generic carvedilol phosphate extended-release capsules rather than biosimilar development. Carvedilol is a small molecule, so the relevant FDA pathway is an abbreviated new drug application, not a biosimilar application under the Public Health Service Act.

Generic applicants may use Paragraph IV certifications when they assert that listed patents are invalid, unenforceable, or not infringed. A Paragraph IV filing can trigger patent litigation under the Hatch-Waxman framework and may create a 30-month stay of approval, subject to statutory conditions.[4]

Publicly available FDA approval records have identified generic carvedilol phosphate extended-release approvals. The competitive field may include companies operating under ANDAs, private-label arrangements, and distributor agreements. The identity of active commercial suppliers can change faster than the Orange Book because a product may remain approved while a manufacturer stops marketing it.

What generic entry risks exist for COREG CR?

The highest generic-entry risk is a formulation that matches the reference product’s pharmacokinetic and dissolution behavior while using a differentiated coating system.

A generic applicant can pursue several technical pathways:

Ethylcellulose-based pellet replication

This is the lowest technical-risk route if the applicant can reproduce the release profile with comparable coating permeability and pellet size. It may carry the highest patent and reverse-engineering risk.

Alternative insoluble polymers

A manufacturer could use polyvinyl acetate, ammonio methacrylate copolymers, or combinations of hydrophilic and hydrophobic polymers. The challenge is achieving equivalent release over the required dissolution conditions without creating dose dumping or food-effect differences.

Hydrophilic matrix multiparticulates

Hypromellose, polyethylene oxide, or related matrix formers can create sustained release without an ethylcellulose film. This approach may simplify coating operations but can produce greater sensitivity to agitation, pH, and gastrointestinal transit.

Osmotic or single-unit systems

An osmotic tablet or capsule-in-capsule system could provide controlled release through a different mechanism. It may reduce overlap with pellet-coating claims but would require a new bioequivalence and manufacturing package.

Coated mini-tablets

Mini-tablets can provide a reproducible size distribution and high throughput. Their development risk is higher because tablet compaction, dose uniformity, and coating defects can affect release more sharply than in a well-controlled pellet system.

How strong is the COREG CR patent estate?

The estate is strongest where patent claims combine a specific controlled-release architecture with measurable dissolution or pharmacokinetic limitations. Broad claims covering carvedilol in any sustained-release form are more vulnerable to validity and obviousness challenges than claims tied to a defined multiparticulate design.

Key strength factors include:

Factor	Assessment
Active ingredient	Weak barrier because carvedilol is long established
Extended-release concept	Moderate barrier; multiple technologies are available
Multiparticulate pellet system	Stronger if claims define structure and release
Ethylcellulose coating	Moderate; alternative polymers may be available
Once-daily pharmacokinetics	Strong regulatory requirement but not always a broad patent barrier
Manufacturing know-how	Potentially strong trade-secret barrier
Excipient composition	Useful when linked to performance; weaker when claimed generically
Method of use	Narrower commercial value than formulation protection

Manufacturing know-how may be more important than the public patent portfolio. Coating uniformity, curing conditions, pellet classification, and capsule-filling controls can determine whether a nominally similar formula achieves the required release profile.

What commercial opportunities exist for excipient suppliers?

The market opportunity is concentrated in excipients that improve controlled-release reproducibility, not in commodity capsule materials.

Premium polymer systems

Ethylcellulose dispersions, ammonio methacrylate copolymers, polyvinyl acetate dispersions, and high-performance hypromellose grades can be sold as integrated release-control systems. Suppliers can differentiate through lot-to-lot permeability, particle-size control, and regulatory support.

Ready-to-use coating platforms

Pre-blended polymer, plasticizer, anti-tacking agent, and pigment systems can reduce development time for generic manufacturers. A ready-to-use platform can support faster scale-up and reduce operator-dependent variability.

Functional starter cores

Sugar spheres with narrow particle-size distributions and controlled friability are important for consistent drug layering. Alternative microcrystalline cellulose or coated-core systems can create opportunities where sugar-based systems present stability or processing limitations.

Analytical and formulation services

Excipient suppliers can provide dissolution mapping, design-of-experiments support, coating process development, and comparative release profiling. These services increase switching costs and improve the supplier’s position in abbreviated application development.

Stability-oriented excipient systems

Moisture control, antioxidant compatibility, and low-residual-solvent processing can improve shelf life. Packaging-compatible excipient systems are relevant because polymer films and capsule shells can respond differently to humidity and storage conditions.

How does COREG CR compare with immediate-release carvedilol?

Attribute	COREG CR	Immediate-release carvedilol
Active ingredient	Carvedilol phosphate	Carvedilol
Dosage form	Extended-release capsule	Immediate-release tablet
Administration	Once daily	Usually twice daily
Formulation complexity	High	Low to moderate
Excipient dependence	High	Lower
Generic development cost	Higher	Lower
Main technical barrier	Release profile and bioequivalence	Conventional tablet performance
Patent value	Formulation and use claims	Primarily historical compound and use protection
Commercial differentiation	Convenience and exposure profile	Cost and established prescribing

The extended-release product can command a formulation premium only if prescribers and payers value once-daily dosing, adherence, or patient conversion. Generic entry narrows that premium quickly.

What litigation and settlement issues affect COREG CR?

Hatch-Waxman litigation can delay generic approval when an applicant files a Paragraph IV certification against a listed patent. Settlement agreements may establish a licensed entry date, supply arrangement, authorized-generic structure, or other commercial terms. FTC review may be relevant where an agreement contains restrictions that affect generic entry.[5]

The key diligence questions are:

• Which patents were challenged?
• Was litigation filed within the statutory period?
• Was a 30-month stay triggered?
• Did the parties settle?
• Was an entry date established?
• Does the agreement include an authorized generic?
• Did FDA approval occur before the agreed commercial launch?
• Is the generic product currently marketed?

What is the outlook for COREG CR excipient commercialization?

The strongest opportunity is a differentiated multiparticulate platform that offers equivalent release with lower coating time, lower solvent use, improved scale-up, and a defensible patent position. Suppliers should prioritize polymer systems and process controls that allow generic developers to avoid direct dependence on the reference product’s exact excipient combination.

The market is mature, so volume growth is likely to come from generic substitution, geographic expansion, and supply-chain replacement rather than rapid growth in carvedilol demand. Commercial value will depend on regulatory documentation, reproducibility, and the ability to support multiple strengths with one platform.

Key Takeaways

• COREG CR is a once-daily carvedilol phosphate extended-release capsule.
• Its core formulation strategy uses drug-layered multiparticulates with polymer-controlled release.
• Ethylcellulose, hypromellose, povidone, triethyl citrate, talc, and capsule-shell materials support the product architecture.
• The principal generic barrier is release-profile replication, not active-ingredient exclusivity.
• Alternative polymers, matrix pellets, mini-tablets, and osmotic systems may support design-around strategies.
• Excipient suppliers have the greatest opportunity in functional coating systems, starter cores, analytical support, and scale-up services.
• COREG CR is subject to small-molecule generic competition, not biosimilar competition.
• Orange Book listings and issued patent claims, rather than the product label alone, determine current patent risk.

FAQs About COREG CR Excipients and Commercial Opportunities

What is the most important excipient in COREG CR?

Ethylcellulose is the principal release-controlling excipient because it forms a water-insoluble diffusion barrier around drug-containing pellets. Its coating level, porosity, plasticization, and curing conditions strongly affect carvedilol release.

Can a generic COREG CR use different excipients?

Yes. An ANDA applicant may use a different excipient system if the formulation meets FDA requirements, including pharmaceutical equivalence, bioequivalence, stability, quality, and applicable patent certifications.

Is COREG CR a biologic requiring biosimilar approval?

No. COREG CR contains carvedilol phosphate, a small-molecule active ingredient. Generic applicants use the ANDA pathway rather than the biosimilar pathway.

Which excipient opportunity has the highest commercial value?

Ready-to-use controlled-release coating systems have the highest value because they can reduce formulation development time and improve manufacturing reproducibility. Commodity gelatin, titanium dioxide, and standard capsule materials offer less differentiation.

Can a multiparticulate formulation avoid COREG CR patent claims?

Potentially, depending on the issued claims. A multiparticulate product using a different polymer, release mechanism, pellet structure, or dissolution profile may reduce infringement risk. The determination requires claim-by-claim analysis of the relevant patent family.

References

1. U.S. Food and Drug Administration. (2023). COREG CR (carvedilol phosphate) extended-release capsules: Prescribing information.
2. U.S. Patent No. 7,235,652. (2007). Controlled release formulation of carvedilol. United States Patent and Trademark Office.
3. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. U.S. Food and Drug Administration. (2017). Approved drug products and therapeutic equivalence evaluations: Patent and exclusivity information.
5. Federal Trade Commission. (2013). Authorized generic drugs: Short-term effects and long-term impact.